Navigation Links
FDA: Minnesota Companies Agree to Halt Sale of Amino-acid Products with Unapproved Claims
Date:9/14/2011

SILVER SPRING, Md., Sept. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that two Minnesota companies have agreed to halt distribution of amino-acid products marketed to treat a number of diseases, until requirements of the Federal Food, Drug, and Cosmetic Act are met.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

West Duluth Distribution Co., a corporation doing business as CHK Nutrition, and NeuroResearch Clinics Inc., both of Duluth, Minn., and their owners or principals, signed a consent decree of permanent injunction, which was entered by the U.S. District Court for the District of Minnesota on September 13.

The complaint for permanent injunction alleges that the companies violated the Federal Food, Drug and Cosmetic Act. As alleged in the complaint, CHK Nutrition's amino-acid products are marketed with claims that they may cure, mitigate, or treat diseases. The products are not the subject of approved new drug applications nor do they qualify for exemption from the premarket approval process as investigational new drugs. Therefore, the amino-acid products are unapproved new drugs within the meaning of the Act.

The consent decree prohibits the defendants from distributing any of their amino-acid products into interstate commerce unless and until they remove the drug claims from their websites. The defendants also agreed to hire an expert to review the claims they make for their products and certify that they have omitted all violative claims. Under the decree, FDA can order the defendants to stop distributing their amino-acid products if they fail to comply with the Act or the terms of the decree.  

"By ensuring that CHK Nutrition and NeuroResearch can't distribute these unapproved products, FDA is helping to prevent health risks for consumers that might take these drugs or delay other important treatments," said Dara A. Corrigan, the FDA's associate commissioner for regulatory affairs. "Until these companies meet FDA requirements, they will no longer be able to process or distribute their products."  

The FDA conducted an inspection of CHK Nutrition and NeuroResearch Clinics in July 2010. During that inspection, an FDA investigator observed evidence of the coordination of the sale of CHK Nutrition's products with claims that such products are effective treatments for "neurotransmitter diseases."

In September 2010, the FDA reviewed CHK Nutrition's website and observed a link to NeuroResearch Clinics' website containing extensive discussions about "amino-acid therapy" for the treatment of Parkinson's disease, Alzheimer's disease, depression, obsessive-compulsive disorder, attention-deficit hyperactivity disorder, fibromyalgia, and others.

Despite FDA warnings to stop making unapproved drug claims, CHK Nutrition and NeuroResearch Clinics did not do so.  The FDA conducted a follow-up review of the companies' websites in February 2011 and found an ongoing connection between the sale of CHK Nutrition's products and claims that they can be used to treat diseases.  The FDA believes that, unless restrained by a court, the companies would continue to violate the law.

For more information:

Dietary Supplements

http://www.fda.gov/food/dietarysupplements/default.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

#

Visit the FDA on Facebook

RSS Feed for FDA News Releases [what is RSS?]

Media Inquiries: Tamara Ward, 301-796-7567; Tamara.Ward@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Coloplast Selected By LifeScience Alley to Host Minnesota Medical Device Panel
2. Prime Therapeutics President and CEO Eric Elliott Delivers Speech at University of Minnesota College of Pharmacy Dialogues in Managed Care Leadership 2011
3. BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital
4. New Report from Childrens Hospitals and Clinics Shows Vaccination Rates Declining among Minnesota Children
5. Minnesotans Help Produce As Well As Benefit from Lifesaving Therapies
6. Heart Device Manufacturer in Minnesota and Hospitals in Ohio & Kentucky to Pay Nearly $4 Million to Resolve Fraud Allegations
7. Childrens Hospitals and Clinics of Minnesota Teams With Geek Squad to Open First Ever In-Hospital Precinct
8. Minnesota High School Tournament Sidelines to be More Secure From Sudden Cardiac Arrest
9. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
10. Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
11. ZINO Society, ZZIF Companies Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. Stock-Callers.com assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... and infrastructure. Most providers, however, are unsure how to move forward, given the ... to define a path forward tailored to an organization’s specific needs. , PYA ...
(Date:6/23/2016)... LAKEWOOD, Colo., USA (PRWEB) , ... June 23, ... ... company, and Sanquin Blood Supply Foundation, a not-for-profit organization responsible for clinical transfusion ... completion of patient enrollment for the Pathogen Reduction Evaluation and Predictive Analytical Rating ...
Breaking Medicine News(10 mins):